Increased prevalence of Leishmania-HIV co-infection is the major reason for the recent 48 emergence of leishmaniasis in the Western World (3).
49
The highly toxic pentavalent antimonials (Sb(V)) have been the primary first-line treatment for 50 all type of leishmaniasis in most parts of the world since their discovery in the 1940s. However 51 the increasing frequency of relapses in leishmaniasis patients is forcing the use of other 52 chemotherapeutical agents including amphotericin B, isethionate pentamidine, paromomycin and 53 miltefosine (4, 5). Unfortunately, the majority of these antiparasitic drugs present severe side 54 effects, there is not guarantee of cure and some of them are frequently accompanied by 55 emergence of drug resistance (6-8).
56
Alternative treatments are needed, however advances in drug discovery approaches have not 57 been satisfactory. Although the use of axenic promastigote cultures of Leishmania as a primary 58 screening method has being validated (7-11), the traditional approaches employed to determine 59 the drug effect in culture present several shortcomings. Microscopical counting is prone to error, 60 time consuming and requires trained personnel; the use of tetrazolium salts such as MTT to measure cell viability is labor-intensive and results are not always reliable (12 subcloned into the Leishmania expression vector pLEXSY-Hyg2 (Jena bioscience) ( Figure 1A ). (555 ex /580 em ) using a Typhoon FLA 9500 (GE Healthcare) and analyzed with ImageQuant TL software (GE Healthcare). 
